Skip to main content
. Author manuscript; available in PMC: 2013 Feb 25.
Published in final edited form as: Clin Pharmacol Ther. 2012 May 16;92(1):87–95. doi: 10.1038/clpt.2011.371

Table 3.

Genotype data and dosing recommendation

Category Genotypes Recommendation Total
Poor metabolizer CYP2C19*2/*2 Alternative therapy 82 (2.6%)
Rapid metabolizer CYP2C19*17/*17 Usual care 154 (4.9%)
Intermediate metabolizer CYP2C19*2 Heterozygote, CYP2C19*3 Heterozygote Alternative therapy 601 (19.1%)
Normal metabolizer CYP2C19*1/*1, CYP2C19*17 Heterozygote, CYP2C19*4 Heterozygote Usual care (e.g. clopidogrel 75mg) 2,059 (65.5%)
Indeterminant CYP2C19*5 Heterozygote, CYP2C19*6 Heterozygote, CYP2C19*8 Homozygote, CYP2C19*8 Heterozygote, CYP2C19*12 Heterozygote Usual care 249 (7.9%)